Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Clin Infect Dis ; 61 Suppl 5: S586-93, 2015 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-26553692

RESUMO

BACKGROUND: Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new meningococcal A conjugate vaccine (PsA-TT) is about to be introduced in the EPI of countries in the African meningitis belt, and this study reports on the immunogenicity of the YF-17D vaccines in infants when administered concomitantly with measles vaccine and PsA-TT. METHODS: Two clinical studies were conducted in Ghana and in Mali among infants who received PsA-TT concomitantly with measles and YF vaccines at 9 months of age. YF neutralizing antibody titers were measured using a microneutralization assay. RESULTS: In both studies, the PsA-TT did not adversely affect the immune response to the concomitantly administered YF vaccine at the age of 9 months. The magnitude of the immune response was different between the 2 studies, with higher seroconversion and seroprotection rates found in Mali vs Ghana. CONCLUSIONS: Immunogenicity to YF vaccine is unaffected when coadministered with PsA-TT at 9 months of age. Further studies are warranted to better understand the determinants of the immune response to YF vaccine in infancy. CLINICAL TRIALS REGISTRATION: ISRCTN82484612 (PsA-TT-004); PACTR201110000328305 (PsA-TT-007).


Assuntos
Anticorpos Neutralizantes/sangue , Anticorpos Antivirais/sangue , Esquemas de Imunização , Vacinas Meningocócicas/administração & dosagem , Vacina contra Febre Amarela/administração & dosagem , Vacina contra Febre Amarela/imunologia , Feminino , Gana , Voluntários Saudáveis , Humanos , Lactente , Masculino , Mali , Vacina contra Sarampo/administração & dosagem , Testes de Neutralização
2.
J Virol ; 87(5): 2895-907, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23269797

RESUMO

The yellow fever virus (YFV), the first proven human-pathogenic virus, although isolated in 1927, is still a major public health problem, especially in West Africa where it causes outbreaks every year. Nevertheless, little is known about its genetic diversity and evolutionary dynamics, mainly due to a limited number of genomic sequences from wild virus isolates. In this study, we analyzed the phylogenetic relationships of 24 full-length genomes from YFV strains isolated between 1973 and 2005 in a sylvatic context of West Africa, including 14 isolates that had previously not been sequenced. By this, we confirmed genetic variability within one genotype by the identification of various YF lineages circulating in West Africa. Further analyses of the biological properties of these lineages revealed differential growth behavior in human liver and insect cells, correlating with the source of isolation and suggesting host adaptation. For one lineage, repeatedly isolated in a context of vertical transmission, specific characteristics in the growth behavior and unique mutations of the viral genome were observed and deserve further investigation to gain insight into mechanisms involved in YFV emergence and maintenance in nature.


Assuntos
Genoma Viral , Vírus da Febre Amarela/classificação , Vírus da Febre Amarela/genética , Aedes/virologia , África Ocidental , Sequência de Aminoácidos , Animais , Sequência de Bases , Linhagem Celular , Variação Genética , Genótipo , Células Hep G2 , Humanos , Insetos Vetores/virologia , Fígado/virologia , Dados de Sequência Molecular , Filogenia , RNA Viral/genética , Análise de Sequência de RNA , Proteínas Virais/química , Proteínas Virais/genética , Febre Amarela/genética , Febre Amarela/virologia , Vírus da Febre Amarela/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA